Moderna requests US authorization of COVID shot for kids under 6 | Inquirer
 
 
 
 
 
 

Moderna requests US authorization of COVID shot for kids under 6

/ 09:21 AM April 28, 2022

Moderna Inc said on Thursday it asked U.S. regulators to authorize its COVID-19 vaccine for children under the age of 6, which would make it the first shot against the coronavirus available for those under 5-years-old.

The COVID-19 vaccine from Pfizer Inc and BioNTech SE is authorized for children 5 and older. But their trial results for 2- to 4-year-olds showed a weaker immune response than in adults, forcing the study to be extended to test the third dose. Pfizer has said that data would come in April.

“This does represent an important area of unmet need,” Moderna Chief Medical Officer Paul Burton said in an interview.

“There’s no other vaccine, no other therapy, that these little kids can have,” Burton said. “If they do judge the data to be sufficient, I think from a public health perspective, offering it to these children as quickly as possible is the best thing.”

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Moderna requests for US authorization of COVID shot for kids under 6

A child is administered a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) pediatric vaccine, in San Jose, Costa Rica February 23, 2022. REUTERS/Mayela Lopez/File Photo

Moderna released trial data in March showing that its vaccine was safe and generated a similar immune response in young children as for adults, which was the goal of the study.

The Omicron variant of the coronavirus, which has been shown to evade vaccine immunity compared with earlier versions, was predominant during the pediatric trial. The drugmaker said two doses were around 37% effective in preventing infections in 2- to 5-year-olds and 51% effective for children ages 6 months to 2 years.

Burton did not disclose a time frame for when the U.S. Food and Drug Administration was expected to consider the authorization request.

ADVERTISEMENT

Top U.S. infectious disease expert Dr. Anthony Fauci suggested in an interview last week with CNN that the FDA hopes to review data from the Pfizer/BioNTech vaccine in the age group alongside the Moderna data.

It is not clear how many U.S. parents will want to vaccinate their children in the age group. Only 28% of U.S. children in the 5 to 11 age group are fully vaccinated, and COVID-19 is often milder in children than adults.

The U.S. Centers for Disease Control and Prevention released data on Tuesday showing that 75% of U.S. children had evidence of prior COVID infection in their blood, much of which occurred during the Omicron surge from December through February.

ADVERTISEMENT

Still, Burton urged parents to vaccinate their children.

“COVID is a bad disease. These variants now are highly transmissible,” he said.

“I do believe that getting vaccinated now should protect these kids: protect them against severe disease, hospitalization, protect them against the long-term effects of COVID. So it makes sense to get vaccinated,” Burton added.

The American Academy of Pediatrics last week urged a swift review of the data in a Twitter post, noting declines in other protections such as masking.

“With no known date for an authorized under 5 vaccine, we urge data once available to be submitted and reviewed ASAP so that we can offer a safe, effective vaccine to our littlest children.”

(Reporting by Michael Erman in New Jersey and Julie Steenhuysen in Chicago; Editing by Bill Berkrot)

Want stories like this delivered straight to your inbox? Stay informed. Stay ahead. Subscribe to InqMORNING

Don't miss out on the latest news and information.
TAGS: Moderna
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.




This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.